deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00288080

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer

Sponsor: NRG Oncology

Conditions Prostate Cancer
Interventions Dexamethasone LHRH agonist Oral antiandrogen Prednisone Radiation therapy docetaxel
Updated 17 times since 2017 Last updated: May 23, 2022 Started: Dec 31, 2005 Primary completion: Apr 30, 2014 Completion: May 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00288080, this PHASE3 trial focuses on Prostate Cancer and remains completed. Sponsored by NRG Oncology, it has been updated 17 times since 2005, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2018 · 15 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Mar 2019 · 8 months · monthly snapshot~Mar 2019 – ~Mar 2020 · 12 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Mar 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

▶ Show 12 earlier versions

  1. Dec 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Jun 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Unknown Status → Active Not Recruiting

  3. Jan 2021 — Jun 2021 [monthly]

    Unknown Status PHASE3

  4. Sep 2020 — Jan 2021 [monthly]

    Unknown Status PHASE3

  5. Jun 2020 — Sep 2020 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  6. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  10. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
  • Radiation Therapy Oncology Group
Data source: Radiation Therapy Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Adrian, United States , Akron, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Ames, United States , Anchorage, United States , Anderson, United States , Ann Arbor, United States and 188 more locations